Ablynx Stock

Stocks

15/10/18	AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	RE
27/04/18	Sanofi : sees new acquisitions and drugs reviving growth	RE
17/04/18	Blackstone LP : Sanofi in talks to sell generics arm to Advent for 1.9 billion euros	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
22/03/18	Ablynx : Drugmaker Novo Nordisk looks to former oil boss to energise M&A	RE
07/02/18	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
30/01/18	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
29/01/18	Ablynx : Chipmakers, Sanofi deal dominate European share trading	RE
29/01/18	Ablynx : Novo Nordisk remains on hunt for biopharma deals	RE
22/01/18	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

19/11/20	Immunicum : and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies	AQ
19/06/18	Ablynx : SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE	GL
28/05/18	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
28/05/18	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
25/05/18	Ablynx : NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020	GL

19/06/18	SANOFI : a finalisé l'acquisition d'Ablynx
14/05/18	Les marchés européens marquent une pause, scrutent la politique italienne
14/05/18	Sanofi : A suivre aujourd'hui
14/05/18	SANOFI : détient 95,60% des actions d'ABLYNX
27/04/18	Sanofi : Les taux de change freinent les résultats, T2 terne en vue

Manager	Title	Age	Since
Geert Deschamps CEO	Chief Executive Officer	-	07/03/2025

Director	Title	Age	Since
Kristine de Sutter BRD	Director/Board Member	-	01/04/2019
Pieter Oldenziel BRD	Director/Board Member	-	01/01/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABLYNX	-.--%	+0.09%	-	-	0
LONZA GROUP AG	-0.19%	+1.57%	+3.26%	+7.54%	50.35B
REVOLUTION MEDICINES, INC.	-0.98%	-2.96%	+387.03%	+592.01%	39.32B
IQVIA HOLDINGS INC.	+0.78%	+3.27%	+33.47%	-4.93%	34.69B
BEONE MEDICINES AG	+2.11%	+3.62%	+15.98%	+58.06%	34.08B
CELLTRION, INC.	-1.31%	-3.03%	+2.51%	+25.24%	26.63B
ASCENDIS PHARMA A/S	-0.22%	-4.38%	-	-	16.49B
MEDPACE HOLDINGS, INC.	-0.64%	+0.60%	+71.15%	+116.37%	15.31B
EUROFINS SCIENTIFIC SE	+1.07%	+3.97%	+15.66%	+18.69%	13.8B
ICON PUBLIC LIMITED COMPANY	-0.18%	+1.92%	+15.85%	-31.17%	12.87B
Average	+0.03%	-0.82%	+68.11%	+97.73%	27.06B
Weighted average by Cap.	+0.04%	-0.73%	+82.21%	+122.35%